There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Invitae (NVTA) and Geron (GERN) with bullish sentiments.
Invitae (NVTA)
In a report released today, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Invitae, with a price target of $48.00. The company’s shares closed last Thursday at $45.69.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 28.4% and a 51.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
Invitae has an analyst consensus of Moderate Buy, with a price target consensus of $43.75, which is a -2.7% downside from current levels. In a report issued on November 3, Leerink Partners also maintained a Buy rating on the stock with a $44.00 price target.
See today’s analyst top recommended stocks >>
Geron (GERN)
Needham analyst Chad Messer assigned a Buy rating to Geron today and set a price target of $3.00. The company’s shares closed last Thursday at $1.83.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 10.2% and a 47.0% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Geron with a $4.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
